James D. Griffin is an American physician-scientist. He is currently Professor of Medicine at Harvard Medical School, Chair of Medical Oncology at Dana–Farber Cancer Institute, and Director of Medical Oncology at Brigham and Women's Hospital.[1][2] He is considered an expert in medical oncology and is widely recognized for his research in the clinical and biologic aspects of hemotologic malignancies.
James D. Griffin | |
|---|---|
| Born | James Douglas Griffin |
| Alma mater | |
| Scientific career | |
| Institutions | |
Griffin completed a Bachelor of Arts at Brown University in 1970. He attended Harvard Medical School, earning his M.D. in 1974. Griffin completed his residency at Johns Hopkins Hospital, a hematology fellowship at Massachusetts General Hospital, and a medical oncology fellowship at Dana–Farber Cancer Institute.[3]
He is on the scientific advisory boards of Phio Pharmaceuticals, the Georgetown Lombardi Comprehensive Cancer Center, and the Johns Hopkins Cancer Center.[4]
Griffin was born in Syracuse, New York. He is a seventh-generation Irish American.[5]
References
edit- ^ "James D. Griffin, MD - Dana-Farber Cancer Institute | Boston, MA". www.dana-farber.org. Retrieved 2022-02-05.
- ^ "James D. Griffin, MD - DF/HCC". www.dfhcc.harvard.edu. Retrieved 2022-02-05.
- ^ Corporation, RXi Pharmaceuticals. "RXi Pharmaceuticals Appoints Medical Oncology Expert, Dr. James Griffin, to Scientific Advisory Board". www.prnewswire.com. Retrieved 2022-02-05.
- ^ walid (2021-06-28). "Phio Pharmaceuticals | About Us". phiopharma.com. Retrieved 2022-02-05.
- ^ "James Griffin". Irish America. Retrieved 2022-02-05.
External links
edit- James D. Griffin publications indexed by Google Scholar
   | This biographical article related to medicine in the United States is a stub. You can help Wikipedia by expanding it. |